(P20-029-23) Xylooligosaccharide Ameliorates Insulin Resistance by Alleviating Gut Microbiota Dybiosis and Modulating NKG2D Signaling in Gestational Diabetes Mellitus Women

Objectives: Gut microbiota (GM), intestinal barrier and natural killer receptor G2 (NKG2D) signaling play synergistic roles in the occurrence and development of insulin resistance (IR) and gestational diabetes mellitus (GDM). Clinical and animal studies have shown that the prebiotics xylooligosaccharides (XOS) can ameliorate IR in prediabetes and type 2 diabetes. However, little is to date known about the bioactivities of XOS in GDM women. This study aimed to investigate if XOS alleviate IR in GDM women and explore its potential mechanism by analyzing GM and NKG2D signaling pathway.

Methods: A double-blind, randomized controlled trial was performed in GDM women by orally supplementing food-grade XOS (4g/d) for 8w. Fasting blood insulin (FBI) and glucose, glycosylated hemoglobin (HbA1c) and homeostasis model assessment of IR (HOMA-IR) were determined. Gut microbiota were detected by using 16S rRNA high-throughput sequencing and NKG2D signaling-related molecules by ELISA.

Results: As compared to control group (n=8), XOS significantly reduced (p < 0.05) FBI, HbA1c and HOMA-IR, and increased (p < 0.05) GM diversity, the Bacteroidetes to Firmicutes ratio and the relative abundance of Akkermansia muciniphila and Bifidobacterium, and decreased (p < 0.05) the serum levels of interleukin 15 (IL-15), lipopolysaccharides (LPS) and NKG2D ligands (MICA and MICB) in GDM women (n=8).

Conclusions: XOS can ameliorate IR by alleviating GM dybiosis and modulating NKG2D signaling pathway in GDM women.

Funding Sources: National Natural Science Foundation of China (NSFC, No 82103824)